Skip to content


DermaGold® Shockwave Therapy for Wound Care: Meta-Analysis Results

DermaGold® Shockwave Therapy for Wound Care: Meta-Analysis Results


Title of study: DermaGold 100 Wound Care Meta-Analysis

Author: Philip Lavin, PhD, FASA, FRAPS

This study covers the effectiveness and safety of Extracorporeal Shock Wave Therapy (ESWT), specifically DermaGold and Orthowave 180, in wound care treatment. The DermaGold® wound care meta-analysis reviewed six studies on the use of extracorporeal shock wave therapy (ESWT) for various wound care indications, including chronic and acute wounds, diabetic foot ulcers, and burn debridement. The study found that ESWT using DermaGold was superior to control for effectiveness while non-inferior for safety. ESWT exceeded both efficacy and safety performance goals, with a 20% absolute efficacy advantage and a 10% absolute safety disadvantage over control for the five randomized studies. The study also found that ESWT had a mean 29.9% advantage over control for effectiveness, exceeding the pre-planned alternative hypothesis of a 20% absolute advantage. For safety, ESWT had a mean 7% advantage over control, exceeding the pre-planned alternative hypothesis of a 5% ESWT absolute advantage. The study was based solely on peer-reviewed published DermaGold studies in the literature. Overall, the study provides evidence for the benefits of ESWT using DermaGold for wound care indications, offering a potentially effective and safe treatment option.

Click here to read more.